Table 1.
TFE3 protein expression in renal cancers.
| negative | focal/weak positive | positive | |
|---|---|---|---|
| CCRCC (n = 1288) | 1107 (85.9%) | 176 (13.7%) | 5 (0.4%) |
| PRCC (n = 109) | 92 (84.4%) | 17 (15.6%) | 0 |
| CHRCC (n = 95) | 88 (92.6%) | 7 (7.4%) | 0 |
| CCPRCT (n = 27) | 26 (96.3%) | 1 (3.7%) | 0 |
| RO (n = 48) | 45 (93.7%) | 3 (6.3%) | 0 |
| TFE3-RCC (n = 35) | 0 | 6 (17.1%) | 29 (82.9%) |
| TFEB-RCC (n = 2) | 0 | 2 | 0 |
| ALK-RCC (n = 1) | 0 | 1 | 0 |
| RCC-FMS (n = 3) | 3 | 0 | 0 |
| CDC (n = 9) | 6 (66.7%) | 3 (33.3%) | 0 |
| PRNRP (n = 7) | 6 (85.7%) | 1 (14.3%) | 0 |
| INI1-RCC (n = 3) | 3 | 0 | 0 |
| FH-RCC (n = 7) | 2 (28.6%) | 4 (57.1%) | 1 (14.3%) |
| BHPRCC (n = 1) | 1 | 0 | 0 |
| RCC-NOS (n = 42) | 32 | 7 | 3 |
CCRCC, clear cell renal cell carcinoma; PRCC, papillary renal cell carcinoma; CHRCC, chromophobe renal cell carcinoma; CCPRCT, clear cell papillary renal cell tumor; RO, renal oncocytoma; RCC-FMS, RCC with fibromyomatous stroma; CDC, collecting duct carcinoma; PRNRP, papillary renal neoplasm with reverse polarity; BHPRCC, biphasic hyalinizing psammomatous renal cell carcinoma. RCC-NOS, renal cell carcinoma, not otherwise specified.